Cargando…
Gamma Knife Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer Patients Treated with Immunotherapy or Targeted Therapy
SIMPLE SUMMARY: In non-small cell lung cancer patients with brain metastases, combined Gamma Knife radiosurgery and immunotherapy or targeted therapy showed an increase in overall survival. The combination of Gamma Knife radiosurgery and immunotherapy or targeted therapy did not increase complicatio...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7762317/ https://www.ncbi.nlm.nih.gov/pubmed/33297416 http://dx.doi.org/10.3390/cancers12123668 |
_version_ | 1783627776611319808 |
---|---|
author | Cho, Anna Untersteiner, Helena Hirschmann, Dorian Shaltout, Abdallah Göbl, Philipp Dorfer, Christian Rössler, Karl Marik, Wolfgang Kirchbacher, Klaus Kapfhammer, Irene Zöchbauer-Müller, Sabine Gatterbauer, Brigitte Hochmair, Maximilian J. Frischer, Josa M. |
author_facet | Cho, Anna Untersteiner, Helena Hirschmann, Dorian Shaltout, Abdallah Göbl, Philipp Dorfer, Christian Rössler, Karl Marik, Wolfgang Kirchbacher, Klaus Kapfhammer, Irene Zöchbauer-Müller, Sabine Gatterbauer, Brigitte Hochmair, Maximilian J. Frischer, Josa M. |
author_sort | Cho, Anna |
collection | PubMed |
description | SIMPLE SUMMARY: In non-small cell lung cancer patients with brain metastases, combined Gamma Knife radiosurgery and immunotherapy or targeted therapy showed an increase in overall survival. The combination of Gamma Knife radiosurgery and immunotherapy or targeted therapy did not increase complications related to radiosurgery. Therefore, the combined treatment seems to be a safe and powerful treatment option for non-small cell lung cancer patients with brain metastases. ABSTRACT: The combination of Gamma Knife radiosurgery (GKRS) and systemic immunotherapy (IT) or targeted therapy (TT) is a novel treatment method for brain metastases (BMs) in non-small cell lung cancer (NSCLC). To elucidate the safety and efficacy of concomitant IT or TT on the outcome after GKRS, 496 NSCLC patients with BMs, who were treated with GKRS were retrospectively reviewed. The median time between the initial lung cancer diagnosis and the diagnosis of brain metastases was one month. The survival after the initial BM diagnosis was significantly longer than the survival predicted by prognostic BM scores. After the first Gamma Knife radiosurgery treatment (GKRS1), the estimated median survival was 9.9 months (95% CI = 8.3–11.4). Patients with concurrent IT or TT presented with a significantly longer survival after GKRS1 than patients without IT or TT (p < 0.001). These significant differences in the survival were also apparent among the four treatment groups and remained significant after adjustment for Karnofsky performance status scale (KPS), recursive partitioning analysis (RPA) class, sex, and multiple BMs. About half of all our patients (46%) developed new distant BMs after GKRS1. Of note, no statistically significant differences in the occurrence of radiation reaction, radiation necrosis, or intralesional hemorrhage in association with IT or TT at or after GKRS1 were observed. In NSCLC-BM patients, the concomitant use of GKRS and IT or TT showed an increase in overall survival without increased complications related to GKRS. Therefore, the combined treatment with GKRS and IT or TT seems to be a safe and powerful treatment option and emphasizes the role of radiosurgery in modern BM treatment. |
format | Online Article Text |
id | pubmed-7762317 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-77623172020-12-26 Gamma Knife Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer Patients Treated with Immunotherapy or Targeted Therapy Cho, Anna Untersteiner, Helena Hirschmann, Dorian Shaltout, Abdallah Göbl, Philipp Dorfer, Christian Rössler, Karl Marik, Wolfgang Kirchbacher, Klaus Kapfhammer, Irene Zöchbauer-Müller, Sabine Gatterbauer, Brigitte Hochmair, Maximilian J. Frischer, Josa M. Cancers (Basel) Article SIMPLE SUMMARY: In non-small cell lung cancer patients with brain metastases, combined Gamma Knife radiosurgery and immunotherapy or targeted therapy showed an increase in overall survival. The combination of Gamma Knife radiosurgery and immunotherapy or targeted therapy did not increase complications related to radiosurgery. Therefore, the combined treatment seems to be a safe and powerful treatment option for non-small cell lung cancer patients with brain metastases. ABSTRACT: The combination of Gamma Knife radiosurgery (GKRS) and systemic immunotherapy (IT) or targeted therapy (TT) is a novel treatment method for brain metastases (BMs) in non-small cell lung cancer (NSCLC). To elucidate the safety and efficacy of concomitant IT or TT on the outcome after GKRS, 496 NSCLC patients with BMs, who were treated with GKRS were retrospectively reviewed. The median time between the initial lung cancer diagnosis and the diagnosis of brain metastases was one month. The survival after the initial BM diagnosis was significantly longer than the survival predicted by prognostic BM scores. After the first Gamma Knife radiosurgery treatment (GKRS1), the estimated median survival was 9.9 months (95% CI = 8.3–11.4). Patients with concurrent IT or TT presented with a significantly longer survival after GKRS1 than patients without IT or TT (p < 0.001). These significant differences in the survival were also apparent among the four treatment groups and remained significant after adjustment for Karnofsky performance status scale (KPS), recursive partitioning analysis (RPA) class, sex, and multiple BMs. About half of all our patients (46%) developed new distant BMs after GKRS1. Of note, no statistically significant differences in the occurrence of radiation reaction, radiation necrosis, or intralesional hemorrhage in association with IT or TT at or after GKRS1 were observed. In NSCLC-BM patients, the concomitant use of GKRS and IT or TT showed an increase in overall survival without increased complications related to GKRS. Therefore, the combined treatment with GKRS and IT or TT seems to be a safe and powerful treatment option and emphasizes the role of radiosurgery in modern BM treatment. MDPI 2020-12-07 /pmc/articles/PMC7762317/ /pubmed/33297416 http://dx.doi.org/10.3390/cancers12123668 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Cho, Anna Untersteiner, Helena Hirschmann, Dorian Shaltout, Abdallah Göbl, Philipp Dorfer, Christian Rössler, Karl Marik, Wolfgang Kirchbacher, Klaus Kapfhammer, Irene Zöchbauer-Müller, Sabine Gatterbauer, Brigitte Hochmair, Maximilian J. Frischer, Josa M. Gamma Knife Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer Patients Treated with Immunotherapy or Targeted Therapy |
title | Gamma Knife Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer Patients Treated with Immunotherapy or Targeted Therapy |
title_full | Gamma Knife Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer Patients Treated with Immunotherapy or Targeted Therapy |
title_fullStr | Gamma Knife Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer Patients Treated with Immunotherapy or Targeted Therapy |
title_full_unstemmed | Gamma Knife Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer Patients Treated with Immunotherapy or Targeted Therapy |
title_short | Gamma Knife Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer Patients Treated with Immunotherapy or Targeted Therapy |
title_sort | gamma knife radiosurgery for brain metastases in non-small cell lung cancer patients treated with immunotherapy or targeted therapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7762317/ https://www.ncbi.nlm.nih.gov/pubmed/33297416 http://dx.doi.org/10.3390/cancers12123668 |
work_keys_str_mv | AT choanna gammakniferadiosurgeryforbrainmetastasesinnonsmallcelllungcancerpatientstreatedwithimmunotherapyortargetedtherapy AT untersteinerhelena gammakniferadiosurgeryforbrainmetastasesinnonsmallcelllungcancerpatientstreatedwithimmunotherapyortargetedtherapy AT hirschmanndorian gammakniferadiosurgeryforbrainmetastasesinnonsmallcelllungcancerpatientstreatedwithimmunotherapyortargetedtherapy AT shaltoutabdallah gammakniferadiosurgeryforbrainmetastasesinnonsmallcelllungcancerpatientstreatedwithimmunotherapyortargetedtherapy AT goblphilipp gammakniferadiosurgeryforbrainmetastasesinnonsmallcelllungcancerpatientstreatedwithimmunotherapyortargetedtherapy AT dorferchristian gammakniferadiosurgeryforbrainmetastasesinnonsmallcelllungcancerpatientstreatedwithimmunotherapyortargetedtherapy AT rosslerkarl gammakniferadiosurgeryforbrainmetastasesinnonsmallcelllungcancerpatientstreatedwithimmunotherapyortargetedtherapy AT marikwolfgang gammakniferadiosurgeryforbrainmetastasesinnonsmallcelllungcancerpatientstreatedwithimmunotherapyortargetedtherapy AT kirchbacherklaus gammakniferadiosurgeryforbrainmetastasesinnonsmallcelllungcancerpatientstreatedwithimmunotherapyortargetedtherapy AT kapfhammerirene gammakniferadiosurgeryforbrainmetastasesinnonsmallcelllungcancerpatientstreatedwithimmunotherapyortargetedtherapy AT zochbauermullersabine gammakniferadiosurgeryforbrainmetastasesinnonsmallcelllungcancerpatientstreatedwithimmunotherapyortargetedtherapy AT gatterbauerbrigitte gammakniferadiosurgeryforbrainmetastasesinnonsmallcelllungcancerpatientstreatedwithimmunotherapyortargetedtherapy AT hochmairmaximilianj gammakniferadiosurgeryforbrainmetastasesinnonsmallcelllungcancerpatientstreatedwithimmunotherapyortargetedtherapy AT frischerjosam gammakniferadiosurgeryforbrainmetastasesinnonsmallcelllungcancerpatientstreatedwithimmunotherapyortargetedtherapy |